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Background
Accumulating evidence has demonstrated that cytokine-
induced killer (CIK) cell immunotherapy may improve
outcomes when used as an adjuvant to current standard
treatment. Previous studies showed that cell signaling
through MHC I-related Chain A (MICA)-Natural killer
group 2, member D (NKG2D) results in CIK cells acti-
vation leading to cytolytic activities against tumor cells.
In this study, we determine the relationship between the
expression of MICA in gastric cancer tumors after D2
gastrectomy and the clinical outcome of a CIK contain-
ing adjuvant therapy.
Methods
From January 2009 to March 2012, ninety-five consecutive
patients with gastric cancer after D2 gastrectomy who
received adjuvant chemotherapy combined with CIK cell
therapy were enrolled (Table 1). The MICA expression of
their tumors was determined by immunohistochemistry
(IHC). The IHC score of was obtained by adding the
intensity and percentage scores.
Results
The MICA protein was detected mainly at the cell
membrane and in the cytoplasm (Fig.1). High-expression
of MICA protein, with IHC scores of 5-7, was documen-
ted in 38 of 95 tumor samples (40.0%). The MICA sta-
tus was significantly association with the age and stage,
p=0.008 and p=0.023, respectively (Table 2). Phenotypic
analysis of NKG2D on in vitro expanded CIK cells
showed that the percentage of NKG2D+ in CD3+/CD56
+, CD3-/CD56+, and CD3+/CD8+ cells populations
were 97.2±1.4%, 97.9±1.8%, and 95.6±2.1%, respectively.
For the 95 patients, the median DFS was 42.0 months,
95% CI = 40.82-43.18 months, and median OS was 45.0
months, 95% CI = 41.82-48.18 months, the 3-year and
4-year DFS rates were 70.5% and 34.7%, respectively,
and the 3-year and 4-year OS rates were 82.1% and
49.5%, respectively (Fig. 2A). For patient with high
MICA expressing tumors the median DFS and OS were
longer than for the patients with tumors with low
expression of MICA; 46.0 months vs. 41.0 months
(p=0.027), and 48.0 months vs. 42.0 months (p=0.031),
respectively(Fig. 2B, Table 3). In a multivariate analysis,
stage and MICA expression were independent prognos-
tic factors for DFS and OS (Table 4).
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Table 1
Variable N m DFS p-value m OS p-value
Sex Male 66 42.0 0.373 44.0 0.229
Female 29 42.0 50.0
Age <65 67 41.0 0.588 48.0 0.464
≥65 28 43.0 43.0
Histological
grade
G1-G2 48 43.0 0.480 48.0 0.556
G3-G4 47 31.0 43.0
Stage II 44 50.0 0.001 51.0 0.006





57 41.0 0.250 43.0 0.257
PF 38 42.0 46.0
CIK cycles <5 54 40.0 0.046 42.0 0.075
≥5 41 48.0 50.0
MICA status High 38 46.0 0.027 48.0 0.031
Low 57 41.0 42.0
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Figure 1
Table 2
Characteristics Total95 MICA highN=38 MICA lowN=57 p-value
Sex Male 66 25 41 0.524
Female 29 13 16
Age <65 67 21 46 0.008
≥65 28 17 11
Histological grade G1-G2 48 23 25 0.111
G3-G4 47 15 32
Stage II 44 23 21 0.023
III 51 15 36
Adjuvant Chemotherapy Xelox, Folfox4 57 25 32 0.347
PF 38 13 25
CIK cycles <5 54 18 36 0.128
≥5 41 20 21
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Conclusion
Our findings show that adjuvant chemotherapy plus CIK
therapy treatment is a promising modality for treating
gastric cancer patients after D2 gastrectomy. Especially,
those who have tumors with high-expression of MICA
were more likely to benefit from such a treatment strat-
egy. Subsequent studies in clinical trial cohorts will be
required to confirm the clinical utility of these markers.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P61
Cite this article as: Chen et al.: Tumor mica status predicts the efficacy
of immunotherapy with cytokine-induced killer cells for patients with
gastric cancer. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P61.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution




Characteristics Number Constituent ratio
Sex Male 66 69.5%
Female 29 30.5%
Age <65 67 70.5%
≥65 28 29.5%
Histological grade G1-G2 48 50.5%
G3-G4 47 49.5%
Stage II 44 46.3%
III 51 53.7%
Adjuvant Chemotherapy Xelox, Folfox4 57 60.0%
PF 38 40.0%
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